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Diabetes mellitus is a growing health concern both abroad and within South 
Africa, as 8.3% of the entire South African population was estimated to be 
afflicted with this condition in 2013 and is projected to increase to 9.9% by 
2035. Most T2DM animal models have defective leptin signalling, which 
does not mirror the human condition. The aim of the study was to investigate 
the type 2 diabetes related changes in the neuroanatomy and neurogenic 
activity of the Zucker Diabetic Sprague Dawley (ZDSD) rat, a rodent model 
with an intact leptin signalling pathway. The ZDSD rats were monitored for 
the development of T2DM, by measuring changes in body mass, fasting 
blood glucose, insulin resistance and lipid profiles. The anatomical structure 
(volume and cell counts) of the ZDSD rat hippocampus was assessed with 
Cresyl violet staining. The neurogenic activity within the model was 
assessed with Ki-67 and DCX immunohistochemistry. Changes in the 
concentration of serum analytes (MDA and BDNF) were also measured in 
the ZDSD rats. The ZDSD rats became overtly diabetic with classical 
features of weight loss, hyperglycaemia, hypercholesterolemia and insulin 
resistance. The ZDSD rats experienced severe oxidative stress, which had 
a strong correlation to hyperglycaemia. BDNF levels remained unchanged 
and had no correlation to hyperglycaemia or neurogenesis. The ZDSD rats 
developed atrophy within the hippocampal dentate gyrus, associated with a 
decline in granule cell layer volume. Furthermore, there was a decline in 
numbers and size of individual granule cells in the granule cell layer, as well 
as increased granule apoptosis. Adult hippocampal neurogenesis was also 
impaired in this rodent model, as shown by a reduction in Ki-67 and DCX 
immunoreactivity.   In conclusion T2DM was successfully modelled in the 
ZDSD rats. Diabetes related changes were found in the structure and 
neurogenic activity of the hippocampal DG. Possible mechanisms for these 
changes could be attributed to oxidative stress and neuro-inflammation 
within the ZDSD rats. Interestingly BDNF appeared to serve no role within 
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CHAPTER 1: BACKGROUND 
1.1 Introduction 
Diabetes mellitus is a growing health concern, as 451 million people were 
estimated to live with this disease in 2017 and the figures were projected to 
increase with an additional 242 million cases by 2045 (Cho et al., 2018). 
Similarly in 2013 8.3% of the entire South African population was estimated 
to be afflicted with this condition and projected to increase to 9.9% by 2035 
(Guariguata et al., 2014). This can be directly associated with a shift towards 
a more western life style. Furthermore diabetes and its complications have 
a significant economic effect on healthcare systems globally (Bagust et al., 
2001).  
Animal models have been developed due to ethics regarding the study of 
human disease, without the use of human subjects. One of the main 
challenges associated with the use of animals is finding a model that 
accurately reflects the human variant of the same disease process 
(Takahashi et al., 2012). Several animal models of T2DM have been 
developed. However there are various discrepancies in the results of the 
different models due to variation in species, inborn errors within animal 
models, protocols and methods (Ho et al., 2013). Most T2DM models uses 
defective monogenic mutations in leptin signalling. Leptin has been shown 
to play a role in hippocampal function. Therefore any pathology seen in 
hippocampal structure and neurogenesis in T2DM animal models 
associated leptin defective signalling maybe attributed to the leptin defect, 
DM or both (McGregor and Harvey, 2019, Chang, 2011).   
The ZDSD rat model is a polygenic model with intact leptin signalling that 
spontaneously develops T2DM. The aim of the study was to investigate 
diabetic related changes in the neuroanatomy and neurogenic activity of the 
ZDSD rat model with an intact leptin pathway. As well as to elucidate 




1.2 Aim and Objectives 
1.2.1 Aim 
The proposed study was designed to determine changes in the 
neuroanatomy and neurogenic activity in the hippocampus of the Zucker 
Diabetic Sprague Dawley Rat. 
 
1.2.2 Objectives 
1.2.2.1 To confirm the development of type diabetes mellitus in the ZDSD 
rat by monitoring body mass, oral glucose tolerance, and fasting circulating 
metabolites (cholesterol, triglycerides and glucose). 
1.2.2.2. To determine the type 2 diabetes mellitus related changes in serum 
levels of brain derived neurotropic factor (BDNF) and malondialdehyde 
(oxidative stress marker) in the ZDSD rats using ELISA. 
1.2.2.3 To determine type 2 diabetes mellitus related changes in cell 
proliferation and neuronal differentiation in the ZDSD rat hippocampus using 
Ki 67 and DCX immunohistochemistry respectively. 
1.2.2.4 To determine type 2 diabetes mellitus related changes in 
hippocampal volume & numerical density and neuronal death in the 










CHAPTER 2: LITERATURE REVIEW 
2.1 Diabetes in South Africa and Abroad  
Diabetes mellitus (DM) is a chronic disorder of carbohydrate metabolism, 
which forms part of a large group of metabolic diseases characterised by 
high blood glucose concentrations. The disease arises from either a relative 
or an absolute lack of pancreatic insulin production and secretion, 
resistance to the action of insulin in the target tissue or both, resulting in 
hyperglycaemia if left untreated (Association, 2014, Ho et al., 2013, 
Wrighten et al., 2009). A recent study determined that men (8.9%) were 
more prone to developing diabetes compared women (8.4%). In 2017, it 
was estimated that 451 million people, aged between 18-99 years, were 
living with DM worldwide and this value is expected to increase with an 
additional 242 million by 2045. It was thought that 49.6% of people living 
with DM in 2017 were still undiagnosed. Furthermore, it was estimated that 
374 million people suffered from impaired glucose tolerance, a disease with 
the potential of developing into full-blown DM. In 2017, DM was directly 
responsible for roughly 5 million deaths in people aged between 20-99 years 
(Cho et al., 2018). The main concern regarding morbidity and mortality 
associated with diabetes stems from diabetic complications rather than the 
actual disease (Cefalu, 2006).     
In 2011, the International Diabetes Federation estimated that 6.5% of the 
South African population was afflicted with DM and that the number would 
increase to 7.2% by 2030 (Whiting et al., 2011). However, as early as 2013 
8.3% of the South African population was already estimated to have 
diabetes and the number was set to reach 9.9% in 2035 (Guariguata et al., 
2014). Some of the factors that contribute to the high occurrence and 
increase in new cases are high obesity rates, urbanisation and economic 
transition associated with a change in nutrition, change to sedentary lifestyle 




South Africa is at risk of these contributing factors due to a shift towards a 
more western lifestyle. Therefore, taking all the above-mentioned facts into 
consideration DM is a major threat to public health both in South Africa and 
abroad. 
 
2.2. Types of Diabetes  
Diabetes mellitus is mainly sub-divided into type one and type two, based 
on aetiology and insulin response. Type one (T1DM), also known as insulin-
dependent diabetes, is caused by the autoimmune destruction of pancreatic 
β-cells, resulting in an absolute insulin deficiency. Therefore, at the time of 
presentation these patients have a severely limited capacity for insulin 
production and require insulin injections. Type two (T2DM), also known as 
insulin-resistant diabetes, is caused by the development of insulin 
insensitivity in the peripheral tissues, causing the paradox of 
hyperglycaemia and hyperinsulinaemia  (Ho et al., 2013, Oyenihi et al., 
2015, Sadeghi et al., 2016a, Wrighten et al., 2009). Type one DM usually 
presents during childhood and occurs in 5-10% of diabetic patients. In 
contrast,  T2DM usually presents in adulthood and accounts for 90-95% of 
diabetic cases (NDIC, 2011, Cefalu, 2006).  
 
2.3 Type Two Diabetes Mellitus  
2.3.1 Aetiology 
Type two diabetes mellitus stems from a diverse aetiological basis, with 
lifestyle and genetics being the dominant culprits. A number of lifestyle 
choices have been known to contribute to the development of the disease, 
with physical inactivity, sedentary lifestyle, smoking, obesity and a high fat 




In this regard, intervention studies have shown that changes in diet, 
exercise and weight loss reduced the incidence of obese subjects 
developing T2DM (Tuomilehto et al., 2001, Knowler et al., 2002). There is a 
strong link between genetics and the incidence of T2DM.  
A parental transmission study found that the risk of developing T2DM is 
higher in children born to diabetic mothers and the risk further increased if 
the father was also diabetic (Meigs et al., 2000). The incidence of T2DM in 
twins is higher in monozygotic twins than dizygotic twins (Kaprio et al., 
1992). In a review by Murea et al. (2012) researchers found that certain 
ethnic groups have a higher risk of developing T2DM. Genome wide 
association studies have identified a number of susceptibility genes for 
T2DM, as well as genes that are implicated in both obesity and T2DM 
(Imamura and Maeda, 2011, Murea et al., 2012). Lastly environmental 
factors has been shown to contribute to the development of T2DM (Murea 
et al., 2012). With the above-mentioned in mind T2DM is not caused by 
simply one instigator, but rather a blend of lifestyle choices, environmental 
factors and genetic susceptibility predisposes an individual to developing 
the condition.     
 
2.4 Glucose Metabolism 
2.4.1 Digestion and absorption 
Dietary carbohydrates are commonly consumed as complex 
polysaccharides. Amylase enzymes, found in the oral cavity and pancreatic 
juice, hydrolyse glycosidic linkages to break these complex molecules into 
smaller oligosaccharides. The cells of the brush border in the small 
intestines contain enzymes that hydrolyse specific disaccharides into their 
corresponding monosaccharides (e.g. glucose). Glucose is absorbed from 
the intestinal lumen via sodium dependent glucose transporter type 1 
(GLUT 1) and released into the bloodstream via glucose transporter type 2 
(GLUT 2).  
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Once in the bloodstream, glucose is utilised by various cells as an energy 
source. Glucose is transported, via GLUT 1, through the blood brain barrier 
(BBB) into the extracellular fluid, down the concentration gradient. This 
transporter also facilitates glucose uptake in astrocytes. In contrast, glucose 
transporter type 3 (GLUT 3) allows for neuronal uptake of glucose 
(Vasudevan et al., 2013, Chen et al., 2016).        
 
2.4.2 Metabolism 
Glucose serves as the main source of energy for the brain, to maintain its 
physiological functions. Once inside the neuronal cells, glucose enters the 
glycolytic cycle. A seen in Figure 2.1, during the preparatory phase of 
glycolysis glucose is phosphorylated by hexokinase into glucose-6-
phosphate (G6P). This is the first irreversible step of the cascade and locks 
glucose in the cell. Thereafter, it is isomerised by phosphohexose 
isomerase to fructose-6-phosphate. Phosphofructokinase further 
phosphorylates fructose-6-phosphate to fructose-1,6-bisphosphate. In the 
splitting phase aldolase cleaves fructose-1,6-bisphosphate into 
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. 
Dihydroxyacetone phosphate is isomerised by isomerase into 
glyceraldehyde-3-phosphate. The net result is two molecules of 
glyceraldehyde-3-phosphate. These molecules are dehydrogenated and 
simultaneously phosphorylated to 1,3-bisphosphoglycerate, under the 
influence of glyceraldehyde-3-phosphate dehydrogenase. Through 
oxidative phosphorylation 1,3-bisphosphoglycerate is converted into 3-
phophoglycerate by bisphosphoglycerate kinase and it is isomerised into 2- 
phosphoglycerate by phosphoglucomutase. Enolase converts 2- 
phosphoglycerate into phosphoenol pyruvate (PEP). Phosphoenol pyruvate 
is dephosphorylated to pyruvate by pyruvate kinase. The glycolytic pathway 




Under aerobic conditions, such as in the brain, the pyruvate molecules are 
decarboxylated to acetyl CoA (coenzyme A), which enters the citric acid 
cycle in the mitochondria and produces a further 30 ATP molecules 
(Mergenthaler et al., 2013). 
A small portion of glycolysis occurs via the pentose phosphate pathway 
(PPP), in which G6P is converted into 6-phosphogluconate and thereafter 
into ribulose-5-phosphate. It is at this point that ribulose-5-phosphate can 
re-join the glycolytic pathway downstream of G6P. During the PPP NADPH 
(reduced Nicotinamide Adenine Dinucleotide phosphate) is generated 
which maintains glutathione in a reduced state to protect against oxidative 
stress.   
 




2.5 Hippocampal Anatomy and Function 
2.5.1 Hippocampal anatomy 
The hippocampal formation is a combination of brain regions including, but 
not limited to the hippocampus, dentate gyrus, parahippocampal gyrus, 
subiculum  and entorhinal cortex (Schultz and Engelhardt, 2014).  
The hippocampus is a curve shaped structure located in the medial portion 
of the anterior temporal lobe. The hippocampus can be divided into an 
anterior and posterior region in primates or ventral and dorsal regions in 
rodents respectively (Fanselow and Dong, 2010).  
The hippocampus has four morphologically different sub-regions, namely 
hippocampus proper, DG, pre-subiculum and subiculum (Andersen et al., 
2007, Yau et al., 2015). The hippocampus proper is sub-divided into several 
zones of pyramidal cells, Cornu Ammonis (CA) 1-4  (Felten et al., 2015). As 
shown in Figure 2.2 the DG has three layers, namely the polymorphic cell 
layer, granule cell layer and molecular layer. The polymorphic cell layer 
consists of several different types of cells. The granule cell layer consists of 
granule cells and pyramidal basket cell bodies. The molecular layer consists 
mostly of the dendrites of the granule cells, as well as the perforant pathway 
(axons of entorhinal cortex layers II and III) and interneurons (Amaral et al., 
2007).  
The hippocampus is extensively interconnected via monosynaptic and 
trisynaptic circuits. The trisynaptic circuits originates within EC layers II and 
III, which synapses with the dendrites of the granular cell layer. Their axons 
(mossy tract fibers) innervate the CA3 pyramidal cells and project back to 
the EC via the Schaffer collateral pathway. The monosynaptic pathway 

















Figure 2.2: Photomicrograph of a sagittal section of the rat hippocampus at 
a X4 magnification. All abbreviations can be found in the list of 
abbreviations.   
 
2.5.2 Hippocampal function 
Each region has its own functions (Moser et al., 1995, Henke, 1990). The 
posterior hippocampus plays a role in cognitive functions, such as learning 
and memory. It is involved in two types of memory, namely spatial memory 
and declarative memory. Moser et al. (1995) demonstrated, through lesion 
studies, that spatial memory was negatively affected by damage to the 
dorsal hippocampus, during the Morris water maze, while lesions to the 
ventral hippocampus had no such effect. In contrast the ventral 
hippocampus aids in stress response, by regulating the hypothalamic-
pituitary-adrenal axis (HPA) and emotions (Fanselow and Dong, 2010). 
Hyperactivity of the HPA axis correlate to reduced hippocampal volumes, 
associated with depression. Henke (1990)  demonstrated that damage to 








2.6.1 Process and types of neurogenesis 
Neurons are the smallest functional units of the nervous system and serve 
to process and transmit information. Astrocytes and oligodendrocytes are 
known as glia and serve a supporting role in the nervous system, to ensure 
its proper function (Zhao et al., 2008). Neurogenesis is a complex series of 
events comprised of the proliferation of neural progenitor cells, 
differentiation, migration, integration, of these newly produced cells, into 
neural circuits and lastly apoptosis of old and damaged cells (van Praag et 
al., 2002). It was thought that neurogenesis only occurred for a specific 
period of time during mammalian development. However, 57 years ago 
neuroblasts were first demonstrated in adult rats and 36 years after that 
neurogenesis was observed in the human DG (Altman, 1962, Eriksson et 
al., 1998). It is now widely accepted that neurogenesis continues throughout 
life in two neurological niches in the adult brain, namely the SVZ of the 
lateral ventricle and the SGZ of the DG in the hippocampus.  (Ho et al., 
2013, Zhao et al., 2008). 
Radial glial-like stem cells (type one cells) undergo asymmetric cell 
divisions, giving rise to amplifying (type two) intermediate neuronal 
progenitor cells. These cells have a higher proliferative capacity and are 
more differentiated than the stem cells. Type two cells differentiate into 
neuroblasts (type three cells). The neuroblasts in the SVZ migrate via the 
rostral migratory stream into the olfactory bulb where they differentiate into 
granule neurons or peri-glomerular neurons.  In contrast the neuroblasts in 
the SGZ migrate into the granule cell layer of the DG, where they extend 
axonal projections into the CA3 pyramidal cell layer and dendrites into the 
molecular layer. During this post-mitotic stage of neurogenesis the newly 
proliferated cells integrate into the local neuronal circuitry, where some cells 
are selected for survival (Encinas et al., 2011, Stanfield and Trice, 1988, 
Jessberger and Kempermann, 2003).  
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However a substantial amount of newly proliferated cells are eliminated 
from the system by apoptosis, under physiological conditions during the 
early post-mitotic period (Biebl et al., 2000, Kempermann et al., 2004). 
Microglia regulate neurogenesis by providing support to the newborn cells 
and apoptosis and clearance of cells that fail to integrate (Ryan and Nolan, 
2016, Sierra et al., 2010). The cells that survive become terminally 
differentiated and indistinguishable from the older granule cells, as seen in 
the switch from calretinin (post-mitotic cells) to calbindin (mature cells) 
expression. Cell counts at this stage remain relatively consistent 
(Kempermann et al., 2004).   
 
2.6.2 Functions of adult hippocampal neurogenesis (AHN) 
Several functions for this key process have been postulated. Neurogenesis 
also serves as a repair mechanism for traumatic brain injuries. Braun et al. 
(2002) demonstrated an increase in neurogenic cells and partial recovery of 
damaged hippocampal and cortical areas.  
Neurogenesis is a physiological process (learning and memory, as well as 
behaviour) required for normal function, as well as preventing several 
diseases. Kempermann (2002) argued that the function of neurogenesis is 
to refine how information is processed (pattern separation), because aging 
animals learn relatively well despite having a reduced level of neurogenesis. 
Neurogenesis also regulates behaviour (anxiety, stress resilience). Revest 
et al. (2009) demonstrated that reduced hippocampal neurogenesis 
increased anxiety related behaviour  
 
2.6.3 Regulation of neurogenesis 
Neurogenesis is a highly regulated processed, influenced by both 
physiological and pathological factors.  
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Physical activity e.g. voluntary running and hippocampal dependent 
learning significantly increased the amount of surviving newly proliferated 
cells in the DG (Van Praag et al., 1999, Gould et al., 1999). Enriched 
environments had a positive effect on neurogenesis, by ensuring the 
survival of one to three week old immature neurons (Tashiro et al., 2007). 
Stress and aging are two negative physiological regulators of neurogenesis. 
Chronic stress reduces neurogenesis via the repeated activation of the 
hypothalamic- pituitary-adrenal axis, resulting in excessive glucocorticoid 
release. This is supported by decreased neurogenesis by corticosterone 
and increased neurogenesis after adrenalectomy. A reviewed by Mirescu 
and Gould (2006). The neurogenic niche shows age dependant decline in 
neurogenesis. There is a debate as to whether the cause is due to a decline 
in function and or number of neural stem cells. This can be due to a decline 
in neurotrophic factors e.g. fibroblast growth factor-2 (FGF-2), insulin-like 
growth factor-1 (IGF-1), vascular endothelial growth factor-2 (VEGF-2) and 
decline in Wnt 3 signalling (Bernal and Peterson, 2004, Okamoto et al., 
2011, Shetty et al., 2005).      
The cells in the neurogenic niche of the DG are exposed to a variety of 
neurotransmitters and neurotrophic molecules from inputs originating in 
several different areas in the brain. However the main transmitters involved 
are glutamate and GABA (Gamma-aminobutyric acid) from the entorhinal 
cortex and interneurons in the DG respectively (Zhao et al., 2008). The 
mechanism by which glutamate functions in neurogenesis remains 
debatable. In contrast GABA has been shown to promote differentiation, by 
stimulating a depolarisation of type two progenitor cells, which resulted in 
increased expression of NeuroD (Tozuka et al., 2005). Brain Derived 
Neurotrophic Factor is produced in the cortical regions and hypothalamus. 
It is a neuroprotective protein that plays a role in proliferation, differentiation 
and survival of the new born cells during neurogenesis, as well as regulate 




Scharfman et al. (2005) demonstrated that BDNF infusions into the 
hippocampus of adult rats caused a local increase in neurogenesis with 
widespread effects. However BDNF levels are significantly reduced in 
T2DM patients (Krabbe et al., 2007).  
IGF-1 is produced both in the liver and brain. It plays a role in neuronal 
development, stimulates neurogenesis, controls oxidative stress and 
promotes neuronal cell survival (D'Ercole et al., 2002). FGF-2 is required for 
the maturation of new neurons during hippocampal neurogenesis, but does 
not affect proliferation (Werner et al., 2011). VEGF-2 promoted 
neurogenesis, by stimulating cellular proliferation in the SGZ (Jin et al., 
2002). In a review by Zhao et al. (2008) studies have shown that genetics 
have a profound impact on neurogenesis with several genes being able to 
increase or decrease neurogenesis in their presence or absence.    
In contrast several pathological conditions have been implicated to affect 
hippocampal neurogenesis. Any neuronal damage (ischemia, trauma and 
seizures) have been associated with an upregulation of neurogenesis 
(Kempermann et al., 2004, Braun et al., 2002). Several animal models have 
shown that T2DM is associated with reduced proliferation, differentiation 
and cell survival during neurogenesis. However it is important to note that 
there are several discrepancies between these studies, due to different 
animal models used (Ho et al., 2013).   
 
2.7 Diabetes Mellitus Related Changes in the Brain 
2.7.1 Effect of diabetes mellitus on hippocampal neuroanatomy and function 
Several MRI (Magnetic Resonance Imaging) based studies have found an 
association between T2DM and reduced brain volumes in humans due to 
atrophy. The regions most severely affected include cerebral, amygdala and 




However Gold et al. (2007) found that the hippocampus is one of the first 
brain sites affected by T2DM and that the hippocampal volume had an 
inverse relationship with glycaemic control. Brain alterations got 
progressively worse with an increase in age (Araki et al., 1994, den Heijer 
et al., 2003). Milne et al. (2018) found the hippocampal atrophy to be 
asymmetric, with the right hippocampus showing a higher degree of 
atrophy. In contrast to the norm where hippocampal atrophy on the left is 
greater in healthy adults (Pedraza et al., 2004). Convit et al. (2003) found 
that glucose intolerance in non-diabetic patients was also linked 
hippocampal atrophy and memory deficits. It is important to note that 
glucose intolerance may ultimately progress to frank diabetes, if not properly 
managed. A study conducted by Brands et al. (2007) demonstrated that 
T2DM patients experienced brain changes more rapidly and was more 
severe than T1DM patients.  
Dendrites constitute a reasonably large amount of a neuron’s total volume. 
Thus a reduction in the length of dendrites and dendritic branching may 
contribute to the decline seen in hippocampal volume of diabetic patients. 
As seen in the db/db mouse model (Stranahan et al., 2009, Ho et al., 2013). 
These changes may also negatively impact how signals in hippocampal 
neurons are processed.     
Hippocampal atrophy was accompanied by a decline in cognitive function 
(e.g. episodic memory) (Convit et al., 2003). Okereke et al. (2008) showed 
that T2DM patients had poor general cognition and verbal memory 
compared to age matched controls. Similarly in animal models db/db mice 
showed poor spatial memory in the Morris water maze test (Li et al., 2002).  
Obese Zucker rats had poor hippocampal performance compared to the 
lean controls in learning and memory tests (Winocur et al., 2005). In a 
review by Ho et al. (2013) it was found that diabetes reduced long term 
potentiation in the CA1 region, associated with a decline in cognition.  
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In addition to a cognitive decline Roy and Lloyd (2012) found that T2D 
patients had almost a two-fold increase in the risk of developing depression, 
as compared to a non-diabetic population.   
 
2.7.2 Effect of diabetes mellitus on adult hippocampal neurogenesis 
A disruption in neurogenesis has been reported in several diabetic animal 
models. Both Zucker diabetic rats and the db/db mouse models showed a 
decline in proliferation and survival of newborn cells during diabetic 
hippocampal neurogenesis. However, in contrast the Goto-Kakizaki rat 
showed increased hippocampal proliferation and differentiation remained 
unchanged. This increase could be attributed to the increased loss of 
newborn cells. It is important to note that there are discrepancies in results 
between different models, as well as when comparing results from the same 
models (Ho et al., 2013, Yi et al., 2009, Stranahan et al., 2008).      
 
2.7.3 Mechanisms involved in the diabetes mellitus related changes in:  
2.7.3.1 Brain derived neurotrophic factor (BDNF) 
Stranahan et al. (2009) showed that a decline in BDNF was associated with 
a reduction in dendritic spine density. As well as by increasing the BDNF 
levels via calorie restriction and exercise the morphological alterations seen 
in the dendrites could be attenuated (Stranahan et al., 2009). BDNF also 
has an inverse relationship with lipid peroxidation. In hyperlipidaemic states 
BDNF levels are reduced due to oxidative stress (Krabbe et al., 2007). Low 
BDNF and high glucocorticoids levels impair NSC proliferation and 
differentiation. Diabetes also cause a disruption in a variety of the above 
mentioned neurotransmitters and neurotrophins that aid in the regulation of 





2.7.3.2 Oxidative stress   
The brain is particularly susceptible to the effects of hyperglycaemia, 
because it utilises insulin-independent transport mechanisms and therefore 
glucose entry into the organ is unaffected by low insulin levels (Ebeling et 
al., 1998). Furthermore, due to the physiological characteristics of the brain, 
the neurons are highly susceptible to the damaging effects of oxidative 
stress induced by this hyperglycaemia. The nervous system utilizes a 
significant proportion of the inhaled oxygen (roughly a third), the brain has 
a low level of antioxidant enzymes, especially in the hippocampus and is 
rich in transitional metals and peroxidable fatty acids (Butterfield et al., 2014, 
Cardozo-Pelaez et al., 2000).    
Both intra – and extra cellular high glucose concentrations have been shown 
to cause oxidative stress (Robertson, 2004).Wentholt et al. (2008) showed 
that 8-iso PGF2α, a marker of oxidative stress, excretion was higher in 
diabetics than normal matched controls. Oxidative stress is a disruption in 
the balance between free radical generation and the defensive capabilities 
of antioxidant systems. Free radicals are oxygen or nitrogen containing 
molecules that are highly reactive, due to unpaired electrons. Antioxidants 
counteract ROS, by donating an electron to ROS, thus stabilizing these 
unstable molecules (Betteridge, 2000, Halliwell, 1994). Free radicals have 
a physiological role when maintained in the correct quantity e.g. Nitric Oxide 
aids in blood flow regulation (Minson et al., 2001). However, when they are 
in excess, due to overproduction or accumulation from saturated antioxidant 
systems, they can have a damaging effect.  
Proteins exposed to oxidative stress may undergo conformational changes, 
resulting in a loss or lowered function. Similarly it can cause oxidative 
lesions in DNA, a potential mutagenic risk (Bartsch and Nair, 2004). 
Oxidative stress damages cell membranes and lipoproteins via lipid 
peroxidation and result in MDA production (Lykkesfeldt, 2007). These 
damaging effects often lead to apoptosis of the affected cells.  
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During diabetic hyperglycaemia glycolytic pathways become saturated with 
glucose and excess metabolites (NADH) reduce the activity of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Yan, 2014).There 
are a variety of different metabolic pathways into which the excess glucose 
and glycolytic metabolites can be shunted into (Figure 2.3). These include: 
polyol pathway, hexosamine pathway, protein kinase C, glucose auto-
oxidation and glycation (AGE). All these pathways can produce ROS (Yan, 
2018).     
  
2.7.3.3 Pathways of ROS generation  
A. Mitochondria 
Under physiological conditions electrons are funnelled through the electron 
transport chain, in the mitochondria, to molecular oxygen. During this 
reaction some of the oxygen (0.1%) may be incompletely reduced, forming 
ROS such as superoxide anions. These ROS then leak out from the 
mitochondria. During hyperglycaemic states there is a disruption in the 
amount of electron donors and therefore flux through the chain. This 
disturbance in the electrochemical gradient of the mitochondrial membrane, 
causes excessive ROS leakage from the mitochondria (Rolo and Palmeira, 
2006).  
B. Polyol pathway  
During diabetic hyperglycaemia 30% of the total body glucose is shunted 
into the polyol pathway (Cheng and González, 1986). Glucose is reduced 
by aldose reductase to sorbitol, during which NADPH is oxidised to NADP+. 
Thereafter sorbitol is oxidised to fructose by sorbitol dehydrogenase, during 
which NAD+ is converted to NADH.  The excess sorbitol, from flux into the 
pathway, accumulates within cells as it cannot cross the cell membrane. 
This exerts an osmotic stress on the cells, reduces Na+/K+ATPase activity 
and impairs axonal transport (Zenker et al., 2013).  
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The increased activity in the pathway also impairs neurotrophic support 
(Suzuki et al., 2004). Ultimately this damages the structure of nerves. The 
consumption of NADPH reduces its availability for the Hexose 
monophosphate shunt pathway, responsible for the production of reduced 
glutathione. Resulting is lower levels of this antioxidant (Yan, 2014). This 
pathway is a source of NADH/NAD+ imbalance, as NAD+ is consumed in 
the conversion to NADH in the second reaction of the pathway. Excess 
NADH overwhelms the mitochondrial electron transport chain and allows for 
more electron leakage from the mitochondria, thus generating more ROS. 
Additionally, excessive NADH levels may inhibit the glycolytic pathway, by 
inactivation of GAPDH. The resultant accumulation in glyceraldehyde-3-
phosphate and glucose amplifies the flux through the glycation and polyol 
pathways (Yan, 2014). Lastly the end product of this pathway is fructose, 
which like glucose tends to form AGE (Gugliucci, 2017).   
C. Hexosamine pathway 
Under physiological conditions a small amount of glucose is metabolised 
via this pathway. During the reaction fructose-6-phophate is converted into 
glucosamine-6-phosphate by glutamine: fructose-6-phophate 
amidotransferase (GFAT). The end product of the pathway is uridine 
diphospahte-N-acetylglucosamine (UDP-GlcNAc) (James et al., 2002). It 
serves as a substrate for the glycosylation of various proteins, especially 
transcription factors (Rolo and Palmeira, 2006). UPD-GlcNAc activates the 
transcription of TGF-β, which plays a role in diabetic complications (Ybarra 
et al., 2010). Increased flux through the Hexosamine pathway is known to 
generate ROS (Rajapakse et al., 2009, Lima et al., 2012).  
D. Protein kinase C  
Hyperglycaemia causes the accumulation of dihydroxyacetone phosphate, 
a glycolytic intermediate.  
After further processing it is converted into diacylglycerol (DAG), which 
serves as an activator of most isoforms of protein kinase C. Activation of 
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this pathway contributes to the increased production of pro-inflammatory 
cytokines (e.g. TNF-α, TGF-β and IL-6), by increasing expression of NF-κB. 
It also contributes to the excess production of ROS and AGE (Evcimen and 
King, 2007, Oyenihi et al., 2015).   
E Autoxidation of glucose 
Wolff and Dean (1987) demonstrated that glucose may undergo 
autoxidation in hyperglycaemic environments. During this reaction 
hydrogen peroxide and reactive ketoaldehydes are generated and 
ultimately highly toxic hydroxyl radicals.   
F. Advanced Glycation End-products (AGE) and Receptor for Advanced 
Glycation End-products (RAGE)  
Advanced glycation end-products are a group of different heterogeneous 
molecules that form from the non-enzymatic maillard reaction between a 
reducing sugar carbonyl group and a free amino group on proteins. To form 
a reversible Schiff base and later an irreversible Amadori product. Further 
reactions between the amadori products and proteins, lipids or DNA result 
in the formation of adducts termed AGEs (Maillard, 1912). Hyperglycaemia 
accelerates the formation of AGE. It results in the accumulation of 
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate in neuronal 
cells. Under normal physiological conditions these glycolytic intermediates 
are converted into methylglyoxal (reactive dicarbonyls), which leads to the 
formation of AGEs. Therefore, during hyperglycaemia methylglyoxal is in 
excess and subsequently increases the amount and speed of AGE 
formation. AGEs have a damaging effect on tissues and tend to accumulate 
in tissues prone to secondary diabetic complications. Where they can 
stimulate immune reactions, affect enzymatic activity and change the half-
life of various proteins (Jack and Wright, 2012, Vlassara and Palace, 2002). 
AGE interacts with cellular surface receptors, especially RAGE and triggers 




The transient activation of these pathways lead to the translocation of NF-
κB, which is responsible for the expression of pro-inflammatory cytokines 
(IL-6 and TNFα). However chronic activation of these pathways increases 
the expression of RAGE, creating a positive feedback loop. Secondly RAGE 
activation suppresses Glo1 expression, an enzyme of the glyoxalase 
pathway responsible for the detoxification of methylglyoxal. (Lukic et al., 
2008, Jack and Wright, 2012, Bierhaus et al., 2004, Xie et al., 2013).  
 
2.7.3.4 Failure of antioxidant systems 
Lenzen et al. (1996) showed that pancreatic islets in a mouse model has 
lower expression of antioxidant enzymes, making them susceptible to 
oxidative damage (Robertson, 2010). Human physiology reflects a similar 
situation. Maxwell et al. (1997) found that on average diabetics had lower 
plasma levels of dietary antioxidants, such as vitamin C. This may be 
attributable to poor diet associated with this western disease. As above 
mentioned the increased flux through the Polyol pathway, negatively 
impacts antioxidant generation via the Hexose monophosphate shunt 
pathway. It is also logical to assume that the antioxidant systems (catalase 
and superoxide dismutase) may become saturated with ROS, thus allowing 
for the accumulation and unhindered activity of these molecules. Further 
more Makar et al. (1995) found that the brains of diabetic mice contained 





Figure 2.3: Pathways of ROS generation. All abbreviations can be found in 
the list of abbreviations.   
2.7.3.5 Neuronal cell death 
Apoptosis is a highly regulated process of physiological cell death. It may 
appear as cell shrinkage and condensation of the nuclear chromatin 
(Méndez-Armenta et al., 2014). Several studies have shown that the 
diabetic brain creates a favourable environment for apoptosis As seen by 
the increased expression of pro-apoptotic markers (Sadeghi et al., 2016a). 
Li et al. (2005) showed that apoptosis in T2D is PARP (Poly (ADP-Ribose) 
polymerase) – mediated. This is reflected in animal models that show a 
reduction in survival of newly proliferated cells.   
Mansouri et al. (2012) used palmitate to simulate a high fat environment, as 
seen in diabetic hyperlipidaemia. They found this impaired the viability of 
neuronal stem cells via lipo-apoptosis. The overproduction of ROS induces 
pro-apoptotic signals (free radical damage and cell stress), causing the 
formation of pores in the mitochondrial membrane.  
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It results in the liberation of cytochrome C from the dysfunctional 
mitochondria (Sadeghi et al., 2016b). Cytochrome C activates caspase 9 
and subsequently caspase 3, resulting in apoptosis of the cell.  
Li et al. (2001) found that hyperglycaemia exacerbated ischaemia induced 
brain damage through the persistent release of cytochrome C and activation 
of caspase 3. Free radicals also disrupt mitochondrial function, resulting in 
a decline in ATP generation within neurons and an irreversible drop in 
membrane potential. This in turn activates other mechanisms off cell death 
(Mastrocola et al., 2005). ROS have been shown to activate cellular 
signalling pathways, resulting in the transcription of stress-associated 
genes. These transcripts e.g. NF-κB promote the transcription of pro-
inflammatory cytokines e.g. TNF-α and IL-6. NF-κB further exacerbates the 
low antioxidant defence in the brain, by down regulating Nrf-2 (Sandireddy 
et al., 2014). Chronic inflammation also results in the production of ROS 
thus creating a positive feedback loop between oxidative stress and 
inflammation (Oguntibeju, 2019). Monje et al. (2003) demonstrated that 
neuroinflammation contributes to neuronal stem cell dysfunction and inhibits 
neurogenesis, but can be reversed by the use of anti-inflammatory drugs. 
The effect of IL-6 seems to be time dependent, with short exposure reducing 
neuronal stem cell proliferation and prolonged exposure increasing the 
number of proliferating neurons (Oh et al., 2010, Ryan and Nolan, 2016). 
TNF-α was shown to inhibit neuronal progenitor cell differentiation and in its 
absence proliferation was increased (Iosif et al., 2006, Johansson et al., 
2008, Ryan and Nolan, 2016). These changes in the sensitive environment 
of the brain may trigger the activation of microglia, these cells respond by 
releasing various pro-inflammatory cytokines. Many of which are cytotoxic, 
as discussed by Russo et al. (2011). Thus the combined effects of oxidative 
stress and inflammation in the brain induces increased apoptosis and a 




Figure 2.4: Hyperglycaemia induced oxidative stress causes neuro-
inflammation, resulting in increased apoptosis and reduced neurogenesis. 
All abbreviations can be found in the list of abbreviations.  
 
2.8 Animal Models for type 2 Diabetes 
Animal models have been developed due to ethical concerns regarding the 
use of human subjects in studies involving disease development and 
progression. Therefore animal models serve a vital role in understanding 
the pathophysiological mechanisms behind diabetes and the development 
of drug treatments to combat the disease (Etuk, 2010). They also enable 
researchers to investigate diabetes and its complications in shorter time 
frames and more cost effectively (Cefalu, 2006). One of the main challenges 
associated with current animal models is finding a model that correctly 
mirrors the disease in humans (Takahashi et al., 2012). Type two animal 
models are designed to express either insulin resistance, obesity or failure 
of beta cell compensation, as these are the hallmark features seen in human 
type two diabetes. Some more accurate models reflect a combination of 
features (King, 2012, Wang et al., 2013).  
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A variety of species (swine, feline, primate and rodent) and causative factors 
(chemically -, physically -, dietary - and genetically induced models) have 
been used to initiate and study type two diabetes (Cefalu, 2006, King, 2012). 
The use of chemically induced models to study type two diabetes is highly 
debatable, as it causes β-cell damage with rapid onset of frank diabetes. 
These features are more characteristic of type one diabetes. However when 
administered to neonates in a low dose it causes type two diabetes. It is 
important to note that this diabetes present with moderately increased blood 
glucose and relatively normal lipid levels, which is not very representative 
of metabolic syndrome. Therefore this model is commonly combined with a 
high fat diet to be more accurate (Panchal and Brown, 2010). Streptozotocin 
and Alloxan are the most commonly used agents to induce diabetes in these 
models of which streptozotocin is the most well-known. Both drugs are 
structurally similar to glucose and enter β-cells trough the GLUT-2 receptor. 
Once inside the cells they halt DNA synthesis and cause cell death, which 
results in a selective necrosis of β-cells. Due to the close similarity to type 
one diabetes and the strong oncogenic activity of streptozotocin this model 
is not ideal to evaluate type two diabetes (Etuk, 2010, Panchal and Brown, 
2010).  
Physically induced models rely on the removal of a portion of the pancreas 
to reduce the β-cell population, which results in the failure of the remaining 
cell population to compensate adequately. These models are seldomly 
utilised, because of the high level of technical expertise required, time and 
lengthy list of possible post-operative complications (Etuk, 2010).      
Diet-induced (high fat feed) models rely on the close correlation between 
obesity and diabetes. In these models normal chow is substituted with a 
high fat and energy rich diet, to mimic the western diet as a contributing 
factor to the development of human diabetes. It leads to obesity with the 
associated development of insulin resistance and failure of β-cell 
compensation. The combined effect results in impaired glucose intolerance 
and ultimately diabetes.  
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These models are commonly used to enhance transgenic or knockout 
models, as they place added pressure on β-cells needed to observe the 
effect of a specific gene. In models that do not express the diabetic 
phenotype. Since these models rely on environmental manipulation rather 
than genetic manipulation it is speculated to be a more accurate 
representation of human diabetes than genetically altered models (King, 
2012). 
In transgenic or knockout models animals are genetically engineered to 
under or over express a protein of interest (Etuk, 2010). These models are 
mainly used to identify the role of specific genes in glucose metabolism, 
diabetic pathophysiology and insulin signalling. These models are more 
commonly employed in recent times, but may be relatively expensive (King, 
2012).     
Models of spontaneous obesity are divided into monogenic and polygenic 
depending on the number of genes involved. Monogenic models usually 
have defective leptin signalling. Leptin regulates energy expenditure and 
food intake within the body. It is mainly produced by peripheral adipocytes. 
In low concentrations it stimulates appetite and in high concentrations 
serves as a satiety signal. Several T2DM animal models use mutations in 
leptin signalling to trigger obesity and DM as a result (Chang, 2011).   
However obesity in humans is usually as a result of polygenetic 
mechanisms (King, 2012, Panchal and Brown, 2010). The most common 
monogenic models are the Lepob/ob mouse, Leprdb/dbmouse and ZDF 
(Zucker Diabetic Fatty Rats) models. The Lepob/ob mouse model has a 
mutated leptin protein. It does not completely correspond to human type two 
diabetes due to the lack of complete β-cell failure (King, 2012). In contrast 
both Leprdb/dband ZDF models have a mutated leptin receptor. The 
Lepr
db/dbmouse model cannot be used to confidently study diabetic 
complications due to the short lifespan of these rodents (Wang et al., 2013).  
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The ZDF rodents are less obese, severely insulin resistant and show 
diabetic complications. These rodents rapidly progress to frank diabetes 
caused by the high level of β-cell apoptosis and a decline in GLUT-2 
receptors (King, 2012, Wang et al., 2013). The ZDF is considered the gold 
standard in type two models caused by defective leptin signalling. However 
the obesity is caused by a leptin receptor mutation and the animals become 
diabetic before reaching adulthood. Thus they do not have a pre-diabetic 
state as seen in humans. These features do not reflect human type two 
diabetes (Peterson et al., 2015, Panchal and Brown, 2010).  
Polygenic models more accurately represent the development of human 
obesity, but these models have no wild-type controls. These models include 
KK mice, NZO (New Zealand Obese) mice and ZDSD (Zucker Diabetic-
Sprague Dawley) rats (King, 2012).      
 
2.9 Zucker Diabetic Sprague Dawley Rat 
The model was developed to overcome the obstacles associated with the 
ZDF model. It was created by crossing a homozygous lean ZDF (lean –/–) 
rat with a diet induced obese rat (DIO), a sub-strain of the Charles River 
Laboratory:CD(Sprague Dawley) rat. The offspring was selectively inbred 
for high fat induced obesity and diabetic traits (Reinwald et al., 2009, 
Peterson et al., 2015, Davidson et al., 2014). The ZDSD model 
encompasses the desired traits of both ZDF (progressive beta cell failure 
and intact leptin signalling) and DIO (predisposition to obesity) rat models 
(Griffen et al., 2001, Reinwald et al., 2009). The combination of which 
ensures the spontaneous development of diabetes irrespective of special 
diets.   
Leptin has been shown to play a role in hippocampal function. Therefore 
any pathology seen in hippocampal neurogenesis in T2DM animal models 
associated leptin defective signalling maybe attributed to the leptin defect, 
DM or both (McGregor and Harvey, 2019, Chang, 2011).   
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This model is uniquely similar to humans as it is polygenic in nature with 
intact leptin signalling and presents with a pre-diabetic state, which slowly 
develops into frank diabetes with diabetic complications, as beta cell failure 
and obesity progresses. Recent studies have also noted similar features 
(hyperlipidaemia, hyperglycaemia, hyperinsulinaemia, glucose intolerance) 
between type 2 diabetes in humans and the ZDSD model (Peterson et al., 





















CHAPTER 3: METHODS AND MATERIALS 
3.1 Animals and Experimental Design 
Forty-eight (n=48), 8-week old rats were divided into two experimental 
groups as follows: 
Group 1 (n=24), served as the control group and was made up of male 
Sprague Dawley rats, sourced from National Health Laboratory Services 
(NHLS), Johannesburg, South Africa. 
Group 2 (n=24), served as the experimental group and consisted of male 
Zucker Diabetic Sprague Dawley (ZDSD) rats, acquired from PreClinOmics, 
Indianapolis, USA. ZDSD rats spontaneously develop diabetes when 
placed on a normal rodent chow. 
 
3.2 Animal Housing and Experimental Procedures 
All animals were aged matched and housed individually in acrylic cages at 
the University of the Witwatersrand, Central Animal Services. Housing 
conditions were maintained at a temperature of 22 ± 2°C and a 12h: 12h 
light/dark cycle. All rats were given access to normal rodent chow (Purina 
5008; Lab Diet, St Louis, Missouri, USA) and water ad libitum for a period 
of 10 weeks. All the animals were allowed to acclimatize for a period of 2 
weeks before the start of experiments (Figure 3.1).  
The animals were allowed five weeks to mature to the age where diabetes 
spontaneously develops and were managed according to the developer’s 
guidelines (Peterson et al., 2015). A confirmatory test to measure 
successful initiation and synchronisation of diabetes was performed at the 
start of week 16. The control rats continued to receive the normal rodent 
chow (Purina 5008 rodent chow; LabDiet, St Louis, Missouri, USA) 




Figure 3.1 Timeline of the experimental procedures 
 
3.3 Body Mass 
After the animals were acclimatized (10 weeks of age) body mass was 
measured once a week for the duration of their housing. Measurements 
were taken with an electronic scale (Diamond, US; accurate to 1g). 
 
3.4 Blood Tests 
3.4.1 Fasting blood glucose, triglycerides and cholesterol 
Fasting blood glucose - and triglyceride levels were measured fortnightly to 
monitor the onset and development of diabetes. These analytes were 
measured after the rodents were fasted for 12 hours overnight. Thereafter 
blood was collected from the tail vein using the pin prick method 
(Parasuraman et al., 2010, Oruganti and Gaidhani, 2011). Glucose was 
measured using a glucometer (Accutrend Plus, Roche Diagnostics, 
Germany). A diabetic state in the experimental animals was confirmed by 
two consecutive fasting glucose readings exceeding 13.9 mmol/L (Peterson 
et al., 2015). Triglyceride levels were measured using a GCT (Glucose 






3.4.2 Oral glucose tolerance test  
Glucose tolerance was monitored by performing an oral glucose tolerance 
test (OGTT) once every four weeks. The test was performed by fasting the 
rodents for 12 hours overnight. Fasting glucose (T0) was recorded before 
administering an oral glucose load of 2 g/Kg. Glucose levels were then 
measured in intervals, from blood collected from the tail vein, at 15, 30, 60 
and 120 minutes after the glucose load was administered (Peterson et al., 
2015).    
 
3.4.3 Lipid peroxidation assay 
A Lipid peroxidation assay kit obtained from Sigma-Aldrich (MAK085) was 
used to quantify serum MDA concentrations. All abbreviations can be found 
in the manufacturer’s instructions. The standard was prepared according to 
the manufacturer’s instructions. The samples were prepared in duplicate, 
by mixing twenty microliters of serum with 500 µL of 42 mM sulphuric acid 
and centrifuged. Phosphotungstic acid solution (125 µL) was added and the 
mixture was vortexed. Thereafter the mixture was incubated at room 
temperature for five minutes, after which it was centrifuged at 13000g for 
three minutes. In a separate tube a water/BHT solution was prepared, by 
adding two microliters of BHT (100×) to 100 µL of water. After centrifugation 
the pellet was re-suspended on ice with the water/BHT solution and the final 
volume was adjusted to 200 µL with water.  
After sample preparation 600 µL of the TBA solution was added to each 
sample and standard. The mixtures were then incubated at 95°C for one 
hour. Thereafter the solutions were cooled to room temperature for 10 
minutes on ice. After the samples reached room temperature 300 µL of 1-
butanol and 100 µL of 5M NaCl were added to each sample and standard. 
Thereafter the reaction mixtures were vortexed and centrifuged for three 
minutes at room temperature at 16000g.  
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The top layer of the mixture was transferred into a separate tube and the 1-
butanol was removed. The remaining material was re-suspended in 200 µL 
of ultrapure water. The mixtures were mixed and 200 µL of each reaction 
mixture was added to separate wells on the plate provided. The 
spectrophotometer was blanked using the MDA standard. The colorimetric 
assay method was used measure the absorbance at 532 nm (A532) using a 
pate reader. The MDA concentration was calculated using the equation 
provided in the manufacturer’s instructions.  
 
3.4.4 Brain-derived neurotrophic (BDNF) factor assay 
A commercial ELISA kit was obtained from Sigma-Aldrich (RAB0026) to 
measure serum BDNF levels. After the reagents were brought to room 
temperature 100 µL of each sample and standard was added to separate 
wells in the plate provided, in duplicate. The wells were sealed and 
incubated for two and a half hours at room temperature. Thereafter the 
solution was discarded and the wells washed (four times) with 1× wash 
solution. Thereafter the plate was inverted and blotted on paper towel. The 
1× biotinylated detection antibody (100 µL) was added to each well and 
incubated for one hour with gentle shaking at room temperature. The 
solution was discarded after incubation and the, above mentioned, washing 
step was repeated. HRP-streptavidin solution (100 µL) was added to each 
well and incubated for 45 minutes at room temperature, under gentle 
shaking. Thereafter the solution was discarded and the washing step was 
repeated. Then 100 µL of ELISA colorimetric TMB reagent was added to 
each well and incubated for 30 minutes at room temperature, in the dark 
with gentle shaking. Thereafter 50 µL of stop solution was added to each 
well. The colour intensity was measured at 450 nm, after the optical density 





3.5 Termination Procedures 
At the end of the experiment all rodents were euthanized by intraperitoneal 
injection with one millilitre sodium pentobarbital (Euthanase, 200 mg/ml; 
Kyron Laboratories (Pty) Ltd, South Arica). This anaesthesia is 
recommended for metabolic studies, as it doesn’t affect glucose or insulin 
(Guarino et al., 2013). Blood samples were collected by cardiac puncture 
into serum separator tubes, centrifuged at 3913 rcf (4 °C for 10 minutes) 
and stored at -20°C for biochemical analysis (Oruganti and Gaidhani, 2011). 
Thereafter the animals were perfused transcardially with 0.9% cold saline 
solution for two minutes, followed by 4% paraformaldehyde in 0.1 M 
phosphate buffer (PB, pH 7.4) solution. After perfusion, the brains were 
carefully removed from the skull and fixed overnight in 4% 
paraformaldehyde in 0.1M PB.  
 
3.6 Sectioning of Tissues 
The brains were transferred to 30% sucrose in PBS 0.1 M solution at 4°C, 
until equilibrium was reached. The brains were split along the midline and 
one half was utilised for the study, while the other half was stored in 
antifreeze for further analysis. The brains were then sectioned in a sagittal 
plane at 50 µm, using a cryostat (Shandon Cryotome E, Thermo Fischer 
scientific, UK) at -24 ̊C. Five repeated series of sections were collected free-
floating into 24 multi-well plates containing 0.1 M PB.  The sections were 
mounted on superfrost slides and allowed to air dry prior to staining. The 
first series of sections were stained with Cresyl violet for anatomical 
orientation, volume measurement of the DG, cell density count in the DG 
and cell death count in the DG. Series two and three were used for Ki-67 






3.7 Histology and Immunohistochemistry 
3.7.1 Cresyl violet staining 
Cresyl violet or Nissl staining is commonly used in neurohistology to identify 
brain architecture. It stains RNA molecules blue (Chengetanai, 2014).  
The slides were rehydrated in a series of alcohol baths of decreasing 
concentration 100%, 95%, 70% and 50% for five minutes in each solution. 
Thereafter the slides were placed in deionised water for one minute. The 
slides were then placed in 1% Cresyl violet staining solution for one minute 
before being transferred into distilled water for another minute. Thereafter 
the sections were dehydrated in graded alcohol baths of increasing 
concentration for the same time periods as above mentioned, starting with 
50% alcohol and ending in 100% alcohol. The only difference is the 70% 
alcohol/acetic acid bath, which acted as the differentiation step. The amount 
of time in which the slides remained in the alcohol/acetic acid bath 
depended on the intensity of the Cresyl violet stain and was monitored 
under the stereomicroscope until optimal differentiation was achieved. 
Thereafter dehydration was continued, and after the last dehydration step 
(five minutes in 100% alcohol) the slides were cleared in xylene and cover 
slipped with DPX (Merck chemicals (Pty) Ltd, Wadeville, South Africa).  
 
3.7.2 Immunohistochemistry 
Ki-67 is a marker of proliferation. It is expressed in cells undergoing mitosis, 
but is not expressed in the G0 phase of the cell cycle. DCX a microtubule 
associated protein and is expressed in migrating immature cells (Kim et al., 
2009).  Ki-67 and DCX immunohistochemistry was done according to 
(Nkomozepi et al., 2019). The brain sections were pre-treated for 30 
minutes at room temperature under gentle shaking with an endogenous 




Followed by three 10 minute rinses in 0.1 M PB, the sections were 
subsequently pre-incubated in a blocking buffer solution [ 3% normal goat 
serum, 2% bovine serum albumin, 0.25 % Triton X-100 in 0.1 M PB] for two 
hours under gentle shaking at room temperature to prevent non-specific 
binding.  The sections were then transferred into a primary antibody solution 
[1:1000, rabbit anti-Ki-67 (AB15580, Abcam, UK) or 1:2000, rabbit anti-DCX 
(AB18723, Abcam, UK), in blocking buffer solution] and were then incubated 
for 48 hours at 4°C under gentle shaking. Thereafter sections were 
subjected to three 10 minute rinses in 0.1 M PB before being incubated in a 
secondary antibody solution [1,000 dilution of biotinylated anti-rabbit IgG 
(BA-5000; Vector Laboratories, USA) in blocking buffer solution] for two 
hours at room temperature under gentle shaking. Followed by three 10 
minute rinses in 0.1 M PB. The sections were incubated in an avidin-biotin 
solution [1:125 A and 1:125 B (Vector Laboratories, USA) in 0.1 M PB] for 
one hour. The sections were then transferred into three 10 minute 0.1 M PB 
rinses before being placed in a solution containing 0.05% 3, 3-di-amino-
benzidine tetrachloride (DAB) in 0.1 M PB for five minutes. To each 1 ml of 
this solution, 3.3 μL of 30% H₂O₂ was added and chromatic precipitation 
was visually monitored under a low power stereomicroscope. 
Development was subsequently stopped by placing the sections in 0.1 M 
PB, followed by a final 10 minute rinse in 0.1 M PB. Sections were mounted 
on superfrost slides, left to air dry overnight, dehydrated in a graded series 
of alcohols of increasing concentration, cleared in xylene and cover slipped 
with DPX. To ensure that non-specific staining was not affecting the results, 
control sections taken at random were processed in the same manner, but 
either the primary or the secondary antibody was omitted. No labelled cells 






3.8 Data Analysis 
3.8.1 Qualitative analysis 
Sections were assessed with light microscopy to compare and describe the 
distribution of apoptotic cells and Ki-67 and DCX -immuno-reactive (ir) 
neurons in the hippocampal DG. Brain structures were identified based on 
a rat atlas (Paxinos and Watson, 2006).  
High resolution microscopic images of the hippocampal DG were digitally 
taken using a Leica ICC50 HD digital camera linked to a (Leica biosystems, 
UK) microscope connected to a computer running Leica application suite 
(LAS) software (Leica biosystems, UK). Composite images were then 
prepared with the Adobe Photoshop 7.0 software (Adobe Systems, 
Mountain View, CA). No pixelation adjustment or manipulation of the 
captured images was undertaken, except for the adjustment of contrast and 
brightness levels. The final result was photomicrographs, from where 
measurements could be made. 
 
3.9 Quantitative Analysis 
3.9.1 Volume of the dentate gyrus 
As seen in Figure 3.2 the volume of the GCL (Granule Cell Layer) was 
measured on photomicrographs  of the DG (stained with Cresyl violet), 

















Numerical density in the granule cell layer of the dentate gyrus 
Cell density counts were obtained from six sections that were 250 µm apart 
per animal containing the DG (stained with Cresyl violet). In each section, 
seven quantification fields [132.13 µm (l) x 99.1 µm (h)] at 100X 
magnification were randomly placed on the GCL of the DG and all cells 
falling within this field were quantified. The mean density counts for each 
animal were obtained by averaging the counts from the different 




Figure 3.2: Illustrates the volume measurement of a 




3.9.3 Pyknotic cell count 
Pyknotic cells were identified in Cresyl violet stained sections on the basis 
of their nuclear morphology.  Pyknotic cells were counted in the GCL of all 
the sections of the brain containing the DG, using a Leica IC550 HD 
microscope at 100X magnification.  
 
3.9.4 Granule cell cross sectional areas  
Cross sectional areas of granule cells in the GCL were measured on 
photomicrographs scanned using a Leica IC550 HD microscope at 100X 
magnification and the area tool on imageJ. Only granule neuronal cells 
showing clear cellular boundaries and a nucleolus in the centre were 
measured.   
 
3.9.5 Doublecortin and Ki-67 quantification 
Quantification was carried out in six sections per animal, containing the 
hippocampus. Sections were 250 µm apart, corresponding to anatomical 
landmarks extending from the Bregma -3.00 to -4.08 mm of the rat brain 
atlas (Paxinos and Watson, 2006). Sections were digitized using an 
Olympus CXR10 HD digital camera linked to an Olympus BH2 RFCA 
microscope (40X objective) and immunoreactive cells in the SGZ were 
manually counted using the Cell Counter function of ImageJ (Schneider et 
al., 2012). Immunoreactive cell counts for each section were obtained by 
averaging the counts from the sections taken from each animal. 
Representative photomicrographs of the hippocampal dentate gyrus were 
prepared using Adobe Photoshop 7.0 software (Adobe Systems, Mountain 
View, CA). No pixelation adjustments or manipulation of the captured 





3.10 Statistical Analysis 
All the data expressed as mean and standard deviation was analysed using 
GraphPad Prism (version 7, GraphPad Software Inc, USA). Body mass and 
OGTTs were plotted against time and analysed using a repeated measures 
(RM) two-way analysis of variance (ANOVA) with treatment and time as the 
main effects. Bonferroni’s test was used to identify differences whenever 
the ANOVA detected significant main effects or interactions.  Fasting 
glucose, cholesterol and triglyceride levels were analysed using one-way 
ANOVA, followed by Bonferroni post hoc test.  The volumes, pyknotic 
counts and granule cell counts were compared using student t test. The 
number of Ki-67-ir and DCX-ir cells in the hippocampal dentate gyrus was 
compared using the Mann-Whitney U test with a level of significance of 
















CHAPTER 4: RESULTS 
4.1 Development of Diabetes 
4.1.1 Body mass changes 
Figure 4.1 shows body mass curves of both ZDSD and SD control rats over 
a 10-week period. The main effects of time (F= 54.23, P<0.0001), treatment 
(F= 15.18, P = 0.0046) and their interaction (F= 21.20, P<0.0001) were such 
that the body masses of both ZDSD rats and SD rats progressively 
increased from week 10 – 16. Thereafter, a significant difference in body 
mass was found between the ZDSD rats and the SD control rats. The SD 
control rats continued to increase body mass till week 20. In contrast, the 
ZDSD rats progressively lost body mass from week 16 to week 20. The loss 









Figure 4.1: Graphical representation of the body mass changes (mean and 
SD) of ZDSD rats compared to SD control rats over a period of 10 weeks. 
Diabetic development was accelerated in the ZDSD rats by high fat feeding, 
starting from the 15th week.  Error bars correspond to the SEM, *** indicates 
significant differences between body masses of ZDSD vs SD control rats 
(P< 0.0001; Bonferroni).  All abbreviations can be found in the list of 
abbreviations. 
4.1.2 Changes in fasting blood glucose, triglycerides and 
cholesterol 
Figure 4.2 show the levels of circulating metabolites for both ZDSD and SD 
control rats at week 20. ZDSD rats were overtly diabetic with a mean fasting 
glucose concentration of 20.3  4.68mmol/L as compared to SD control rats 
(mean fasting glucose concentration 3.94  0.55mmol/L; Figure 4.1.2A). An 
independent t-test showed that fasting glucose concentrations in ZDSD rats 
were statistically greater than the non-diabetic controls (t = 19.84; P = 
0.0321). Circulating concentrations of triglycerides were not significantly 
different between the two treatments groups (P = 0.4851; Figure 4.1.2B) but 
cholesterol levels were greater in ZDSD rats compared to the SD control 




Figure 4.2: Graphical representation of the fasting glucose (A), triglycerides 
(B) and cholesterol (C) (mean and SD) in both the ZDSD rats and SD control 
rats at 20 weeks of age. * indicates glucose concentration in ZDSD rats are 


















































































































































cholesterol concentration in ZDSD rats are significantly different from the 
SD control rats (P = 0.0072). All abbreviations can be found in the list of 
abbreviations.  
 
4.1.3 Oral glucose tolerance tests 
Figure 4.3 shows oral glucose tolerance curves for both ZDSD and SD 
control rats over a period of 120 minutes. ZDSD rats exhibited significant 
abnormalities in glucose handling (Figure 4.1.3) at 20 weeks (main effects 
of time (F = 8.81, P < 0.0001), treatment (F = 357.1, P < 0.0001) and their 
interaction (F = 1.982, P = 0.1210). The baseline glucose concentration was 
greater in the ZDSD rats, compared to the SD control rats (P < 0.0001). A 
glucose challenge significantly increased glucose concentrations in the 
ZDSD rats to peak at 27.94  2.78mmol/L after 30 minutes compared to a 
peak of 6.78  1.09mmol/L achieved by Control SD rats at 15 min (P < 
0.0001). The 2-hour glucose concentration of ZDSD rats were similarly 







Figure 4.3: Graphical representation of the glucose tolerance (mean and 
SD) in ZDSD rats compared to SD control rats at 20 weeks of age. *** 
indicates glucose concentrations in ZDSD rats were significantly different 
from SD control rats (P< 0.0001; Bonferroni). All abbreviations can be found 












4.2 Changes in Serum Levels of Brain Derived Neurotrophic Factor 
and Malondialdehyde 
4.2.1 Serum malondialdehyde levels (MDA) 
Figure 4.4 shows the serum levels both ZDSD and SD control rats. At 20 
weeks of age, the ZDSD rats (19.21 ± 6.62nmol/µL) had a significantly 
higher serum concentrations of MDA compared to the SD control rats 
(3.25 ± 2.27nmol/µL).  
 
 
Figure 4.4: Graphical representation of the quantity of oxidative stress 
(MDA) (mean and SD) in ZDSD rats compared to SD control rats at 20 
weeks of age. All abbreviations can be found in the list of abbreviations.  ** 
indicates serum levels of MDA were significantly higher in ZDSD rats than 
in SD control rats (P< 0.001). All abbreviations can be found in the list of 





4.2.2 Brain derived neurotrophic factor (BDNF) 
Figure 4.5 show the levels of serum BDNF in both the ZDSD and SD control 
rats. At 20 weeks of age, there was no significant difference (P=0.975) in 
serum levels of BDNF between SD control rats (15.70ng/mL) and ZDSD 
rats (18.10ng/mL).  
 
Figure 4.5: Graphical representation of the serum BDNF levels in SD 
control rats compared to ZDSD rats at 20 weeks of age. All abbreviations 











4.3 Changes in Hippocampal Morphology 
4.3.1 Total hippocampal dentate gyrus volume 
Figure 4.6 shows the total hippocampal DG volume of both ZDSD and SD 
control rats at week 20. The total DG volume in the ZDSD rats (4.888 ± 
0.08581mm3) was significantly lower than the SD control rats (5.438 ± 



















Figure 4.6: Graphical representation of the total hippocampal DG volume 
(mean ±SD) in both the SD control rats and ZDSD rats at 20 weeks of age.  
** indicates that hippocampal DG volume was significantly reduced in the 
brains of ZDSD rats compared to SD control rats (P<0.005). All 









4.3.2 Total granule cell layer volume 
Figure 4.7 shows the total GCL volume of both the ZDSD and SD control 
rats at week 20. The total GCL volume was significantly higher in the SD 
control rats (0.7465 ± 0.04143mm3) compared to the ZDSD rats (0.6229 ± 




















Figure 4.7: Graphical representation of the GCL volume (mean ±SD) in 
both the Control SD rats and ZDSD rats at 20 weeks of age.  * indicates that 
the total GCL volume was significantly reduced in the brains of ZDSD rats 
compared to SD control rats (P< 0.05). All abbreviations can be found in the 










4.3.3 Granule cell cross sectional area 
Figure 4.8 shows the cross sectional area of individual granule cells in the 
hippocampal granule cell layer of both the ZDSD and SD control rats. At 20 
weeks of age, the cross sectional area of granule cells in the ZDSD rats 
(90.57 ± 0.8386µm2) were significantly lower compared to the SD control 
























Figure 4.8: Graphical representation of the granule cell cross sectional area 
(mean±SD) in both the SD control rats and ZDSD rats at 20 weeks of age.  
*** indicates that the granule cell cross sectional area was significantly 
reduced in the brains of ZDSD rats compared to SD control rats (P< 0.0001). 









4.3.4 Granule cell density 
Figure 4.9 shows the number of granule cells in a camera field (40X 
magnification) were quantified in the GCL of the hippocampal DG of both 
the ZDSD and SD control rats. At 20 weeks of age, the number of granule 
cells were significantly higher in the SD control rats (61.16 ± 0.6823 






















Figure 4.9: Graphical representation of the granule cell count/camera field 
(mean±SD) in the hippocampus of both the SD control rats and ZDSD rats 
at 20 weeks of age. *** indicates that the granule cell count/field was 
significantly lower in the brains of ZDSD rats compared to SD control rats 








4.3.5 Pyknotic cell count in the granule cell layer 
Figure 4.10 shows the number of pyknotic cells in the GCL of the 
hippocampal DG of both ZDSD and SD control rats per camera field. At 20 
weeks of age, the number of pyknotic cells in the GCL were significantly 
higher in the ZDSD rats (7.128 ± 0.3248 count/field) compared to the SD 




















Figure 4.10: Graphical representation of the pyknotic cell count/camera 
field (mean±SD) in the granule cell layer in both the SD control rats and 
ZDSD rats at 20 weeks of age.  *** indicates that the pyknotic cell count/field 
in the GCL was significantly higher in the brains of ZDSD rats compared to 









4.4 Changes in Hippocampal Neurogenic Activity 
4.4.1 Ki-67 expression 
Figure 4.11 shows photomicrographs of Ki-67 expression in the 
hippocampal DG in both ZDSD and SD control rats. The number of Ki-67-ir 
cells were quantified in the SGZ of the hippocampal DG of ZDSD (Figures 
4.11 B and D) and SD control rats (Figures 4.11 A and C). At 20 weeks of 
age the number of Ki-67-ir cells in the SGZ of ZDSD rats (9.6 ± 0.96) were 
significantly reduced by approximately 55% compared to the SD rats (20.7 










Figure 4.11: Photomicrographs showing Ki-67-ir cells in the SGZ of the 
hippocampal DG of both ZDSD rats (B and D) and SD control rats (A and 
C). The black arrows indicate the neuroblast cell bodies and white arrows 
indicate neuroblast cellular processes. The scale bar in A and B represents 
200 µm, while the scale bar in C and D represents 10 µm. All abbreviations 








4.4.2 Doublecortin expression 
Figure 4.12 shows photomicrographs of DCX expression in the 
hippocampal DG in both ZDSD and SD control rats. The number of DCX-ir 
cells were quantified in the SGZ and GCL of the hippocampal DG of ZDSD 
(Figures 4.12 B and D) and SD control rats (Figures 4.12 A and C) per 
section. At 20 weeks of age, the total number of DCX-ir cells in the SGZ and 
GCL of the ZDSD rats (58.6 ± 3.97) were significantly reduced by 
approximately 65% compared to the SD control rats (165.9 ± 11.13; P< 
0.001, Figure 4.13 B). Additionally, DCX-ir neuroblasts in the SGZ of the 
hippocampal DG of SD control rats had well developed vertical dendrites 
that extended into the molecular layer (Figure 4.12 C). Conversely, DCX-ir 
neuroblasts in the hippocampal DG of ZDSD rats had poorly developed 


















Figure 4.12: Photomicrographs showing DCX-ir cells in the SGZ of the 
hippocampal DG of both ZDSD rats (B and D) and SD control rats (A and 
C). The black arrows indicate the neuroblast cell bodies and white arrows 
indicate neuroblast cellular processes. The scale bar in A and B represents 
200 µm, while the scale bars in C and D represents 10 µm. All abbreviations 




Figure 4.13: Graphical representation of Ki-67-ir (A) and DCX-ir (B) cells in 
the hippocampal DG of both ZDSD rats and SD control rats at 20 weeks of 
age. ** indicates Ki-67 and DCX ir-cells in the hippocampal DG of ZDSD 
rats is significantly lower compared to that of the SD control rats (P<0.001). 






































4.5 Correlations of BDNF and MDA with Diabetes and Hippocampal 
Parameters 
Table 4.1 summarizes the Pearson's correlations of serum BDNF and MDA 
levels with various diabetes and hippocampal parameters in SD control and 
ZDSD rats. No significant correlations were found between serum BDNF 
levels and cholesterol (P=0.745), triglycerides (P=0.537), glucose 
(P=0.853), DCX (P=0.992), Ki 67 (P=0.946), DG volume (P=0.347) and 
pyknotic cells (P=0.881).  
Significant positive correlations were observed between serum MDA levels 
and cholesterol (P=0.001), triglycerides (P=0.040), glucose (P=0.001) and 
pyknotic cells (P=0.008). On the contrary, strong negative correlations were 
also observed between serum MDA levels and DCX (P=0.001), Ki 67 
(P=0.001) and DG volume (P=0.000). However, no significant correlations 
were found between serum MDA and BDNF levels (P=0.385). 
 
Table 4.1:  Correlation of BDNF and MDA with various diabetes and 
hippocampal parameters.  





BDNF Corr -0,118 -0,222 0,067 -0,004 -0,025 -0.333 0.055 N/A 
 P  0,745 0,537 0,853 0,992 0,946 0.347 0.881 N/A 
MDA Corr 0.859 0,631 0.884 -0.868 -0.866 -0.939 0.778 0.309 
 P 0,001 0,040 0,001  0,001  0,001 0.000 0.008 0.385 
 
Data are represented as correlation co-efficients (Corr) and p values.  
CHOL – Cholesterol; TG-Triglycerides; Glu-Glucose; DCX-Doublecortin; 
DG Vol-Dentate gyrus volume; Pyk-Pyknotic cells, MDA-malondialdehyde 
and BDNF-Brain derived neurotrophic factor.  
74 
 
CHAPTER 5: DISCUSSION 
This study focused on the hippocampal dentate gyrus, one of the few niches 
for adult neurogenesis. The hippocampal dentate gyrus is crucial for 
learning and memory. The goal of this study was to determine the diabetes 
induced changes in the morphology and neurogenic activity in the 
hippocampal DG using an animal model with an intact leptin-signalling 
pathway, the novel ZDSD rat. This study successfully modelled T2DM 
(obesity, hyperglycaemia, insulin resistance and dyslipidaemia) in the ZDSD 
rat, by assessing body mass, fasting blood glucose, triglycerides, 
cholesterol, oral glucose tolerance and lipid profiles. Hippocampal atrophy 
and pyknosis were evident in the DG of the ZDSD rat. Immunolabeling of 
neuroblasts with Ki-67 and DCX antibodies revealed a reduction in 
proliferation and differentiation of neuroblasts in the hippocampal dentate 
gyrus. Additionally, DCX immunoreactive neuroblasts in the SGZ had fewer 
dendritic extensions to the molecular layer, compared to the SD control rats. 
In an attempt to elucidate the possible mechanism/s behind the 
pathophysiological alterations observed, serum MDA measurements 
revealed increased oxidative stress in the ZDSD rats. However, the serum 
BDNF levels remained unchanged at 20 weeks in ZDSD rats in spite of the 
development of overt diabetes.        
 
5.1 Modeling of Type 2 Diabetes Mellitus in the ZDSD Rat 
The SD control rats weighed more than the ZDSD rats and both showed an 
initial progressive increase in body mass (Figure 4.1.1). Davidson et al. 
(2014) obtained similar results with the same model, however they noted 
the ZDSD rats to be more obese than the SD control rats initially. A possible 
cause for this discrepancy is the difference in age of the animals used at the 
start of each experiment as the ZDSD rats have been shown to develop a 
pre-diabetic state around 7 weeks of age (Peterson et al., 2015). In contrast 
to the SD control rats, the ZDSD rats showed a progressive decline in body 
mass after week 16 due to the initiation of diabetes.  
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The weight loss seen in the diabetic animals are due to insulin resistance in 
the peripheral tissues, resulting in cells being starved of glucose and 
compensating by increasing the breakdown of fat and muscle (Morigny et 
al., 2016). Peterson et al. (2015) and Davidson et al. (2014) found a similar 
weight gain and loss in the ZDSD rats.  
According to Peterson et al. (2015), a diabetic state in the ZDSD rats is 
confirmed by two consecutive fasting glucose readings of greater than 
13.9mmol/l. At 20 weeks of age, the ZDSD rats were overtly diabetic with 
an average fasting glucose reading of 20.3mmol/l (Figure 4.1.2 A). This 
observation was supported by the 20 week OGTTs, showing poor glucose 
handling as a result of peripheral insulin resistance (Figure 4.1.3).    
Triglycerides remained relatively stable between the experimental animals 
and the controls (Figure 4.1.2 B). However, the fasting cholesterol levels 
were significantly greater in the ZDSD rats compared to the controls (Figure 
4.1.2 C). Similar findings were also reported by Peterson et al. (2015) and 
Davidson et al. (2014), using the same ZDSD rat model. These diabetic 
traits are in keeping with several other diabetic animal models reviewed by 
Ho et al. (2013).  
 
5.2 Changes in the Hippocampal Neuroanatomy and Neurogenic 
Activity Induced by T2DM 
5.2.1 Structural changes 
A number of morphological alterations have been reported in the brain, after 
the induction of diabetes e.g. alteration in the expression of various synaptic 
proteins, retraction of dendritic branches in the CA3 region and atrophy 
(Lebed et al., 2008). In this study, at 20 weeks of age the total DG volume 
in the ZDSD rats showed a significant amount of atrophy in comparison to 




This feature of hippocampal atrophy is also reflected in a number of MRI 
based studies in humans with T2DM, as well as T2DM animal models for 
instance db/db mice (Gold et al., 2007, Araki et al., 1994, Ramos-Rodriguez 
et al., 2014). It is important to note that the molecular and sub granular 
zones of the hippocampal DG were not measured in this study. Therefore, 
it is not possible to ascertain whether the T2DM induced reduction in total 
DG volume was solely due to changes in the GCL. However, similar to other 
studies, a reduction in dendritic extensions into the ML as was observed 
with DCX immunohistochemistry, coupled with reduced proliferation in the 
SGZ in this study could point to a involvement of all the layers of the DG  
(Stranahan et al., 2009, Ho et al., 2013). It is thus logical to assume that the 
atrophy seen in the GCL may extend through all three layers of the DG. In 
support of this, Dong et al. (2019) and Li et al. (2020) reported reductions in 
the hippocampal molecular layer of diabetic patients while Cui et al. (2006) 
and Bonds et al. (2020) found reductions in the number of newborn cells in 
the SGZ of the hippocampal DG. 
The atrophy observed in the GCL can be attributed to a number of factors. 
Firstly, from the immunohistochemistry it is evident that neurogenesis 
(proliferation, migration and differentiation of neuroblasts) in the ZDSD 
model is severely reduced. The GCL serves as the site of migration for 
newborn neurons from the SGZ during neurogenesis (Zhao et al., 2008). 
Thus, less cells become incorporated into the GCL (Hwang et al., 2008, Cui 
et al., 2006). Secondly, there is a reduction in the cell size of individual 
granule cells, measured as cross sectional area. This might be as a result 
of chemical stress, pushing cells towards apoptosis (Saraste and Pulkki, 
2000). Thirdly, the ZDSD model exhibits an increased rate of neuronal loss 
within the GCL layer, as a result of increased apoptosis as can be seen from 
the significantly higher pyknotic cell count in the ZDSD rats GCL, compared 
to the SD control rats. Foghi and Ahmadpour (2013) reported similar 




Furthermore, Sonneville et al. (2012) demonstrated a 9 fold increase in 
neuronal apoptosis in the hippocampus of diabetic patients with 
uncontrolled diabetes. Ultimately neurons are being lost at a faster rate than 
the rate at which they are being replaced.  
 
5.2.2 Functional changes 
Both Ki-67 and DCX expression in the GCL of the ZDSD rats were severely 
reduced. Thus, there was both a reduction in proliferation of newborn cells 
and their migration into the GCL. These features are in keeping with other 
reports from studies using other diabetic animal models (Ho et al., 2013, Yi 
et al., 2009, Stranahan et al., 2008). Hwang et al. (2008) also found that the 
reduction in neuronal differentiation got progressively worse with increasing 
age and blood glucose levels in a ZDF model. A reduction in cell survival of 
newborn cells in the SGZ of T2DM animal models have also been well 
documented (Ho et al., 2013, Sadeghi et al., 2016b).  
 
5.3 Possible Mechanisms Behind the Observed Alterations   
The hippocampus is a prime target for hyperglycaemia induced oxidative 
stress due to its physiological features. The brain utilises insulin-
independent transport mechanisms (Ebeling et al., 1998), is a highly aerobic 
organ, has low levels of antioxidant enzymes and is rich in transitional 
metals and peroxidisable fatty acids (Butterfield et al., 2014, Cardozo-
Pelaez et al., 2000). Wentholt et al. (2008) showed that oxidative stress was 
higher in diabetics than normal matched controls. Both intra and extra 
cellular high glucose concentrations have been shown to cause oxidative 





There are several biochemical mechanisms through which diabetes mellitus 
causes oxidative stress (mitochondrial leakage, polyol pathway, 
hexosamine pathway, protein kinase C, glucose auto-oxidation and 
advanced glycation end-products), as reviewed by Giacco and Brownlee 
(2010). Ultimately hyperglycaemia, seen in diabetes causes oxidative stress 
by increasing the influx of glucose through metabolic pathways causing 
damaging metabolites to accumulate and saturating antioxidant systems 
(Zenker et al., 2013, Makar et al., 1995). Interestingly, the effects 
hyperglycaemia can be attenuated by antioxidant treatment (Oyenihi et al., 
2015).  High cholesterol has been shown to have a similar effect to 
hyperglycaemia by being able to induce oxidative stress, as well as increase 
the permeability of the blood brain barrier, thereby allowing potentially 
harmful substances from peripheral circulation to cause neuronal damage 
(Tozuka et al., 2009, Pugazhenthi et al., 2017).    
Malondialdehyde (MDA) is a product of lipid peroxidation, produced during 
oxidative stress (Khoubnasabjafari et al., 2015). At 20 weeks of age, the 
ZDSD rats had a significantly higher concentration of MDA compared to the 
SD control rats. This indicates that the ZDSD rats experienced a significant 
amount of oxidative stress, most likely as a result of the hyperglycaemia and 
hyperlipidaemia observed in the model. This is supported by a strong 
positive correlation between MDA and both fasting glucose and cholesterol 
levels observed in this study (Table 4.5.1). Similarly, Noberasco et al. (1991) 
showed that MDA levels were significantly higher in diabetics, compared to 
healthy controls and that the levels of MDA had a positive reciprocal 
relationship with poor glycaemic control. Oxidative stress damages cellular 
structures such as proteins, DNA and lipids directly through oxidation, 
changing their structure and or function. This in turn also generates reactive 
oxygen species (ROS), creating a positive feedback loop.  
Alternatively oxidative stress damages cells through the formation of 
products such as advanced glycation end products (Bartsch and Nair, 2004, 
Lykkesfeldt, 2007).  
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Advanced glycation end products (AGEs) trigger a series of intracellular 
signalling cascades e.g. activation of NF-κB, resulting in the release of pro-
inflammatory cytokines (IL-6 and TNFα) (Lukic et al., 2008, Jack and Wright, 
2012, Bierhaus et al., 2004, Xie et al., 2013). Free radical damage and cell 
stress caused by oxidative stress and inflammation upregulates pro-
apoptotic signals pushing neuronal cells towards apoptosis (Sadeghi et al., 
2016a, Miller, 2011, Alvarez-Nölting et al., 2012). In support of this, 
Sonneville et al. (2012) demonstrated a 1.5-2 fold increase in the number 
of damaged hippocampal neurons of diabetic patients with uncontrolled 
diabetes and consequently a 9-fold increase in the rate of hippocampal 
neuronal apoptosis. Furthermore, microglial activation associated with 
inflammation, was also observed with a 3.7 to 6-fold increase.   
For neurogenesis to occur a delicate redox balance needs to be maintained 
as ROS serve a physiological role when maintained in specific 
concentrations. As they activate redox-sensitive signalling pathways, an 
oxidized environment favours differentiation and a reduced environment 
favours proliferation. Furthermore, an oxidized environment favours 
astroglial differentiation compared to a reduced environment, which favours 
neuronal differentiation (Huang et al., 2012). As stated above, oxidative 
stress leads to chronic inflammation within the brain, via the activation of 
pro-inflammatory genes e.g. NF-κ-B (Sandireddy et al., 2014). The afore 
mentioned microglial activation is responsible for the release of 
inflammatory cytokines (TNFα, IFNγ, IL-1 and IL-6), several of which have 
been shown to negatively impact neurogenesis by reducing proliferation, 
migration or survival of newborn cells (Sonneville et al., 2012, Ben-Hur et 
al., 2003, Vallieres et al., 2002, Green et al., 2012, Fuster-Matanzo et al., 
2013). Ekdahl et al. (2003) found a significant negative correlation between 
the number of activated microglial cells in the SGZ and the number of 
newborn cells that survive. Furthermore, they found that by selectively 
inhibiting the activation of microglial cells, hippocampal neurogenesis could 
be attenuated in the presence of neuroinflammation.    
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Thus it appears that hyperglycaemia induced oxidative stress and 
neuroinflammation work hand-in-hand to reduce neurogenesis and increase 
neuronal apoptosis, resulting in cognitive impairments. In support of this, 
Cui et al. (2006) showed that chronic glucose exposure caused 
neurodegeneration via increased apoptosis and inhibition of neurogenesis 
(proliferation and migration) in a rodent diabetic model. Furthermore, this 
study has identified a strong negative correlation between MDA and 
neurogenesis (DCX and Ki-67, Table 4.5.1). However, based on the 
literature it appears that neuroinflammation is more responsible for the 
decline in neurogenesis, while oxidative stress is responsible for the 
increased apoptosis in a diabetic setting. This combination results in the 
decline in hippocampal volume and cognitive impairments associated with 
diabetes.    
Brain derived neurotrophic factor is produced in most cortical regions and 
in the hippocampus (von dem Bussche and Tuszynski, 2009). It (BDNF) is 
a neuroprotective protein, known to play a positive role in neurogenesis 
(proliferation, differentiation and cell survival) (Waterhouse et al., 2012, 
Numakawa et al., 2018, Lee et al., 2002). A negative reciprocal relationship 
has been reported to exist between hyperglycaemia (T2DM) and BDNF 
levels (Krabbe et al., 2007), leading many to speculate on the connection 
between low BDNF and reduced neurogenesis seen in DM (Zhen et al., 
2013). Interestingly, in this study no change in BDNF levels were found 
between the diabetic ZDSD and SD control rats. This study further found no 
relationship between hyperglycaemia and serum BDNF levels (Table 4.5.1). 
Karege et al. (2002) reported a positive correlation between serum BDNF 
and cortical BDNF levels. Thus, we can assume that the cortical BDNF 
levels should compare well to the insignificant serum levels. In spite of the 
normal BDNF levels, there was a decline in neurogenesis. Moreover, no 
correlations were found between BDNF with Ki-67 or DCX (Table 4.5.1). 
Thus, BDNF might not be the primary cause or mechanism through which 
adult hippocampal neurogenesis is impaired as seen in T2DM, but might 
worsen the degree of impairment.  
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Divya et al. (2020) found that hyperglycaemia induced oxidative stress and 
inflammation in the brain result in a reduction in BDNF levels. Thus, the 
decline in BDNF levels seen in diabetes might be the result of atrophy of the 
brain regions producing BDNF, therefore the decline in BDNF and 
neurogenesis might be independent events with a common cause. 
Furthermore, Suwa et al. (2006) found a negative correlation between age 
and BDNF levels. Thus, it is likely that if the current study was conducted 
over a longer period of time, a similar decline in BDNF levels would have 




















CHAPTER 6: CONCLISIONS, LIMITATIONS AND RECOMMENDATIONS 
In conclusion, this study has successfully modelled type 2 diabetes in the 
ZDSD rat, by monitoring changes in body mass, fasting blood glucose, 
insulin resistance and lipid profiles. Furthermore, diabetic related changes 
in the rodent brain with an intact leptin pathway were noted and these 
included hippocampal atrophy (in terms of both DG volume and cell counts), 
increased apoptosis in the DG, alongside disruptions in neurogenesis within 
the SGZ as shown by reduced neuronal proliferation, differentiation and cell 
survival. A possible mechanism for the changes found could be attributed 
to increased oxidative stress as seen in the model used in this study. 
Interestingly, the serum BDNF levels suggest that a decline in BDNF, 
associated with diabetes, may not be the mechanism responsible for the 
defects in neurogenesis, but rather an independent synergistic factor. There 
were also similarities noted between other studies of the ZDSD model, as 
well as other type 2 diabetic animal models. Thus this model is well suited 
for the study of T2DM as related to humans and more specifically the study 
for neuronal changes associated with diabetes.  
It is important to note that this study had some limitations. Firstly, only male 
ZDSD rats were used in this study. However, this allows for the exclusion of 
hormonal variables associated with female rats. The female ZDSD rat does 
not spontaneously develop diabetes unless switched to a high fat diet 
(Peterson et al., 2015). The supplier of the ZDSD rats only sells male rats 
to avoid breeding the animals. Secondly, the study relied on use of single 
markers of oxidative stress, proliferation and differentiation due to limited 
financial resources. It is recommended that other markers of neurogenesis 
and techniques such as double labelling be employed in future studies.  
There could be many other possible mechanisms that could work 
independently or in synergy with oxidative stress e.g. inflammation. Thus, 
In future studies involving the ZDSD model, other potential mechanisms 
such as inflammation should be investigated to ascertain their role in the 
changes noted in the hippocampal anatomy and neurogenic activity. 
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Furthermore, future studies should consider increasing the duration of the 
experiment to monitor time-course changes of BDNF, MDA and 
neurogenesis in order to understand the relationship of these with the 























CHAPTER 7: MISCELLANEOUS 
7.1 Ethical Approval 
The welfare of the animals and experimental methodologies were in 
accordance with the ethical principles and standards of the Animal 
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University of Johannesburg. Ethical approval for this study was obtained 
from the Animal Ethics Screening Committee (Clearance number 
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